Breaking Down SG&A Expenses: MorphoSys AG vs Arrowhead Pharmaceuticals, Inc.

A Comparative Analysis of SG&A Expenses: MorphoSys AG vs Arrowhead Pharmaceuticals, Inc.

In the ever-evolving pharmaceutical industry, understanding the financial strategies of leading companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of MorphoSys AG and Arrowhead Pharmaceuticals, Inc. from 2014 to 2023. Over this period, Arrowhead Pharmaceuticals demonstrated a consistent upward trend, with SG&A expenses peaking in 2022, marking a 410% increase from 2014. In contrast, MorphoSys AG experienced more volatility, with a significant spike in 2020, reaching its highest point, which was over 16 times its 2014 expenses. However, by 2023, both companies reported similar SG&A expenses, highlighting a convergence in their financial strategies. Notably, data for MorphoSys AG in 2024 is missing, indicating potential changes or reporting delays. This financial insight provides a window into the strategic priorities and operational efficiencies of these pharmaceutical giants.